A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system
This report aims to provide a comprehensive presentation of the global market for Drugs for Central Nervous System Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Central Nervous System Diseases. This report contains market size and forecasts of Drugs for Central Nervous System Diseases in global, including the following market information:
Global Drugs for Central Nervous System Diseases Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Drugs for Central Nervous System Diseases market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Antidepressants Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drugs for Central Nervous System Diseases include Alkermes, Astrazeneca, Biogen, Bristol Myers Squibb, Lilly, GSK, Merck, Sunovion?Pharmaceuticals and Pfizer, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drugs for Central Nervous System Diseases companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Central Nervous System Diseases Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Drugs for Central Nervous System Diseases Market Segment Percentages, by Type, 2022 (%)
Antidepressants
Anxiolytics
Anti-manic
Other
Global Drugs for Central Nervous System Diseases Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Drugs for Central Nervous System Diseases Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Drugs for Central Nervous System Diseases Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Drugs for Central Nervous System Diseases Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Central Nervous System Diseases revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drugs for Central Nervous System Diseases revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alkermes
Astrazeneca
Biogen
Bristol Myers Squibb
Lilly
GSK
Merck
Sunovion?Pharmaceuticals
Pfizer
Teva
Norvatis
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Central Nervous System Diseases, market overview.
Chapter 2: Global Drugs for Central Nervous System Diseases market size in revenue.
Chapter 3: Detailed analysis of Drugs for Central Nervous System Diseases company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Central Nervous System Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Central Nervous System Diseases Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Central Nervous System Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Central Nervous System Diseases Overall Market Size
2.1 Global Drugs for Central Nervous System Diseases Market Size: 2022 VS 2030
2.2 Global Drugs for Central Nervous System Diseases Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Central Nervous System Diseases Players in Global Market
3.2 Top Global Drugs for Central Nervous System Diseases Companies Ranked by Revenue
3.3 Global Drugs for Central Nervous System Diseases Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Central Nervous System Diseases Companies in Global Market, by Revenue in 2022
3.5 Global Companies Drugs for Central Nervous System Diseases Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Central Nervous System Diseases Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Central Nervous System Diseases Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Central Nervous System Diseases Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Central Nervous System Diseases Market Size Markets, 2022 & 2030
4.1.2 Antidepressants
4.1.3 Anxiolytics
4.1.4 Anti-manic
4.1.5 Other
4.2 By Type - Global Drugs for Central Nervous System Diseases Revenue & Forecasts
4.2.1 By Type - Global Drugs for Central Nervous System Diseases Revenue, 2018-2023
4.2.2 By Type - Global Drugs for Central Nervous System Diseases Revenue, 2024-2030
4.2.3 By Type - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Central Nervous System Diseases Market Size, 2022 & 2030
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Drugs for Central Nervous System Diseases Revenue & Forecasts
5.2.1 By Application - Global Drugs for Central Nervous System Diseases Revenue, 2018-2023
5.2.2 By Application - Global Drugs for Central Nervous System Diseases Revenue, 2024-2030
5.2.3 By Application - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Drugs for Central Nervous System Diseases Market Size, 2022 & 2030
6.2 By Region - Global Drugs for Central Nervous System Diseases Revenue & Forecasts
6.2.1 By Region - Global Drugs for Central Nervous System Diseases Revenue, 2018-2023
6.2.2 By Region - Global Drugs for Central Nervous System Diseases Revenue, 2024-2030
6.2.3 By Region - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Drugs for Central Nervous System Diseases Revenue, 2018-2030
6.3.2 US Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.3.3 Canada Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.3.4 Mexico Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Drugs for Central Nervous System Diseases Revenue, 2018-2030
6.4.2 Germany Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4.3 France Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4.4 U.K. Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4.5 Italy Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4.6 Russia Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4.7 Nordic Countries Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.4.8 Benelux Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Drugs for Central Nervous System Diseases Revenue, 2018-2030
6.5.2 China Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.5.3 Japan Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.5.4 South Korea Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.5.5 Southeast Asia Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.5.6 India Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Drugs for Central Nervous System Diseases Revenue, 2018-2030
6.6.2 Brazil Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.6.3 Argentina Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue, 2018-2030
6.7.2 Turkey Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.7.3 Israel Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.7.4 Saudi Arabia Drugs for Central Nervous System Diseases Market Size, 2018-2030
6.7.5 UAE Drugs for Central Nervous System Diseases Market Size, 2018-2030
7 Drugs for Central Nervous System Diseases Companies Profiles
7.1 Alkermes
7.1.1 Alkermes Company Summary
7.1.2 Alkermes Business Overview
7.1.3 Alkermes Drugs for Central Nervous System Diseases Major Product Offerings
7.1.4 Alkermes Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.1.5 Alkermes Key News & Latest Developments
7.2 Astrazeneca
7.2.1 Astrazeneca Company Summary
7.2.2 Astrazeneca Business Overview
7.2.3 Astrazeneca Drugs for Central Nervous System Diseases Major Product Offerings
7.2.4 Astrazeneca Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.2.5 Astrazeneca Key News & Latest Developments
7.3 Biogen
7.3.1 Biogen Company Summary
7.3.2 Biogen Business Overview
7.3.3 Biogen Drugs for Central Nervous System Diseases Major Product Offerings
7.3.4 Biogen Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.3.5 Biogen Key News & Latest Developments
7.4 Bristol Myers Squibb
7.4.1 Bristol Myers Squibb Company Summary
7.4.2 Bristol Myers Squibb Business Overview
7.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Major Product Offerings
7.4.4 Bristol Myers Squibb Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.4.5 Bristol Myers Squibb Key News & Latest Developments
7.5 Lilly
7.5.1 Lilly Company Summary
7.5.2 Lilly Business Overview
7.5.3 Lilly Drugs for Central Nervous System Diseases Major Product Offerings
7.5.4 Lilly Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.5.5 Lilly Key News & Latest Developments
7.6 GSK
7.6.1 GSK Company Summary
7.6.2 GSK Business Overview
7.6.3 GSK Drugs for Central Nervous System Diseases Major Product Offerings
7.6.4 GSK Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.6.5 GSK Key News & Latest Developments
7.7 Merck
7.7.1 Merck Company Summary
7.7.2 Merck Business Overview
7.7.3 Merck Drugs for Central Nervous System Diseases Major Product Offerings
7.7.4 Merck Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.7.5 Merck Key News & Latest Developments
7.8 Sunovion?Pharmaceuticals
7.8.1 Sunovion?Pharmaceuticals Company Summary
7.8.2 Sunovion?Pharmaceuticals Business Overview
7.8.3 Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Major Product Offerings
7.8.4 Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.8.5 Sunovion?Pharmaceuticals Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Drugs for Central Nervous System Diseases Major Product Offerings
7.9.4 Pfizer Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.9.5 Pfizer Key News & Latest Developments
7.10 Teva
7.10.1 Teva Company Summary
7.10.2 Teva Business Overview
7.10.3 Teva Drugs for Central Nervous System Diseases Major Product Offerings
7.10.4 Teva Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.10.5 Teva Key News & Latest Developments
7.11 Norvatis
7.11.1 Norvatis Company Summary
7.11.2 Norvatis Business Overview
7.11.3 Norvatis Drugs for Central Nervous System Diseases Major Product Offerings
7.11.4 Norvatis Drugs for Central Nervous System Diseases Revenue in Global Market (2018-2023)
7.11.5 Norvatis Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Drugs for Central Nervous System Diseases Market Opportunities & Trends in Global Market
Table 2. Drugs for Central Nervous System Diseases Market Drivers in Global Market
Table 3. Drugs for Central Nervous System Diseases Market Restraints in Global Market
Table 4. Key Players of Drugs for Central Nervous System Diseases in Global Market
Table 5. Top Drugs for Central Nervous System Diseases Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Drugs for Central Nervous System Diseases Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Drugs for Central Nervous System Diseases Revenue Share by Companies, 2018-2023
Table 8. Global Companies Drugs for Central Nervous System Diseases Product Type
Table 9. List of Global Tier 1 Drugs for Central Nervous System Diseases Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Central Nervous System Diseases Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Drugs for Central Nervous System Diseases Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Drugs for Central Nervous System Diseases Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2024-2030
Table 30. Alkermes Company Summary
Table 31. Alkermes Drugs for Central Nervous System Diseases Product Offerings
Table 32. Alkermes Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 33. Alkermes Key News & Latest Developments
Table 34. Astrazeneca Company Summary
Table 35. Astrazeneca Drugs for Central Nervous System Diseases Product Offerings
Table 36. Astrazeneca Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 37. Astrazeneca Key News & Latest Developments
Table 38. Biogen Company Summary
Table 39. Biogen Drugs for Central Nervous System Diseases Product Offerings
Table 40. Biogen Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 41. Biogen Key News & Latest Developments
Table 42. Bristol Myers Squibb Company Summary
Table 43. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product Offerings
Table 44. Bristol Myers Squibb Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 45. Bristol Myers Squibb Key News & Latest Developments
Table 46. Lilly Company Summary
Table 47. Lilly Drugs for Central Nervous System Diseases Product Offerings
Table 48. Lilly Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 49. Lilly Key News & Latest Developments
Table 50. GSK Company Summary
Table 51. GSK Drugs for Central Nervous System Diseases Product Offerings
Table 52. GSK Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 53. GSK Key News & Latest Developments
Table 54. Merck Company Summary
Table 55. Merck Drugs for Central Nervous System Diseases Product Offerings
Table 56. Merck Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 57. Merck Key News & Latest Developments
Table 58. Sunovion?Pharmaceuticals Company Summary
Table 59. Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Product Offerings
Table 60. Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 61. Sunovion?Pharmaceuticals Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Drugs for Central Nervous System Diseases Product Offerings
Table 64. Pfizer Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. Teva Company Summary
Table 67. Teva Drugs for Central Nervous System Diseases Product Offerings
Table 68. Teva Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 69. Teva Key News & Latest Developments
Table 70. Norvatis Company Summary
Table 71. Norvatis Drugs for Central Nervous System Diseases Product Offerings
Table 72. Norvatis Drugs for Central Nervous System Diseases Revenue (US$, Mn) & (2018-2023)
Table 73. Norvatis Key News & Latest Developments
List of Figures
Figure 1. Drugs for Central Nervous System Diseases Segment by Type in 2022
Figure 2. Drugs for Central Nervous System Diseases Segment by Application in 2022
Figure 3. Global Drugs for Central Nervous System Diseases Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drugs for Central Nervous System Diseases Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Drugs for Central Nervous System Diseases Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2022
Figure 8. By Type - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 9. By Application - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 10. By Type - Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 12. By Application - Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 14. By Region - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 15. By Country - North America Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 16. US Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 20. Germany Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 21. France Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 28. China Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 32. India Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 34. Brazil Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue Market Share, 2018-2030
Figure 37. Turkey Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2018-2030
Figure 41. Alkermes Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Astrazeneca Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Biogen Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Bristol Myers Squibb Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Lilly Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. GSK Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Pfizer Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Teva Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Norvatis Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
